Loteprednol
- Generic Name
- Loteprednol
- Brand Names
- Alrex, Lotemax, Zylet
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27ClO5
- CAS Number
- 129260-79-3
- Unique Ingredient Identifier
- Z8CBU6KR16
- Indication
用于眼科局部炎症。0.2％浓度适用于暂时缓解季节性过敏性结膜炎；0.5％混悬液适用于治疗对类固醇有效的炎症，如结膜炎、角膜、前房炎、过敏性结膜炎、痤疮、酒糟鼻、表浅性点状角膜炎、疱疹、带状疱疹角膜炎、虹膜炎、睫状体炎等可适当减轻水肿和炎症。尚可用于眼科手术后炎症的治疗。
- Associated Conditions
- Chickenpox, Conjunctivitis infective, Cyclitis, Eye infection viral, Herpes Zoster Keratitis, Inflammation, Iritis, Ocular Inflammation, Rosacea, Seasonal Allergic Conjunctivitis, Superficial punctate keratitis
Intraocular Pressure With Loteprednol and Dexamethasone
Phase 4
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2008-10-28
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 35
- Registration Number
- NCT00781300
- Locations
- 🇧🇷
Department of Opthalmology, Federal University of São Paulo, São Paulo, SP, Brazil
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Phase 4
Completed
- Conditions
- Conjunctivitis
- Interventions
- Drug: Vehicle of Zylet
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 137
- Registration Number
- NCT00705159
- Locations
- 🇺🇸
Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Phase 3
Completed
- Conditions
- Ocular Inflammation
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 400
- Registration Number
- NCT00699153
- Locations
- 🇺🇸
Cornerstone Eye Wear, High Point, North Carolina, United States
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Phase 4
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- ORA, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00689078
- Locations
- 🇺🇸
Ophthalmic Research Associates, Andover, Massachusetts, United States
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
Phase 3
Completed
- Conditions
- Ocular Inflammation
- Interventions
- Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 400
- Registration Number
- NCT00645671
- Locations
- 🇺🇸
John Hunkeler, MD, Overland Park, Kansas, United States
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 119
- Registration Number
- NCT00560638
- Locations
- 🇺🇸
Ophthalmic Research Associates, Andover, Massachusetts, United States
Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex
Phase 4
Completed
- Conditions
- Inflammation
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 310
- Registration Number
- NCT00532961
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Phase 4
Completed
- Conditions
- Blepharokeratoconjunctivitis
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 276
- Registration Number
- NCT00447577
- Locations
- 🇺🇸
Cornerstone Eye Care, High Point, North Carolina, United States
Pediatric Zylet Safety and Efficacy Study
Phase 4
Completed
- Conditions
- ChalazionHordeolum
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 108
- Registration Number
- NCT00420628
- Locations
- 🇺🇸
Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Phase 4
Completed
- Conditions
- Dry Eye DiseaseKeratoconjunctivitis Sicca
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2011-07-21
- Lead Sponsor
- Ophthalmic Consultants of Long Island
- Target Recruit Count
- 5
- Registration Number
- NCT00407043
- Locations
- 🇺🇸
Ophthalmic Consultants of Long Island, Lynbrook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath